Literature DB >> 29247681

Chemokines in systemic sclerosis.

Jamie King1, David Abraham1, Richard Stratton2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29247681     DOI： 10.1016/j.imlet.2017.12.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN： 0165-2478            Impact factor:   3.685


× No keyword cloud information.
  4 in total

1.  In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Authors:  Yukihiro Kitanaga; Emiko Imamura; Yutaka Nakahara; Hidehiko Fukahori; Yasutomo Fujii; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

2.  Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis.

Authors:  Tetsuya Ikawa; Takuya Miyagawa; Yuki Fukui; Satoshi Toyama; Jun Omatsu; Kentaro Awaji; Yuta Norimatsu; Yusuke Watanabe; Ayumi Yoshizaki; Shinichi Sato; Yoshihide Asano
Journal:  Arthritis Res Ther       Date:  2021-11-13       Impact factor: 5.156

3.  Role of placental inflammatory mediators and growth factors in patients with rheumatic diseases with a focus on systemic sclerosis.

Authors:  Francesca Motta; Veronica Codullo; Véronique Ramoni; Stefania Cesari; Giuseppina Ferrario; Giacomo Fiandrino; Fausta Beneventi; Stefania Rampello; Hanna Johnsson; Carlomaurizio Montecucco; Gerard J Graham
Journal:  Rheumatology (Oxford)       Date:  2021-07-01       Impact factor: 7.580

4.  PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis.

Authors:  Dan Xu; Swati Bhattacharyya; Wenxia Wang; Igal Ifergan; Ming-Yi Alice Chiang Wong; Daniele Procissi; Anjana Yeldandi; Swarna Bale; Roberta Goncalves Marangoni; Craig Horbinski; Stephen D Miller; John Varga
Journal:  JCI Insight       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.